| Literature DB >> 34257588 |
Sophia C Rossouw1, Hocine Bendou1, Renette J Blignaut2, Liam Bell3, Jonathan Rigby4, Alan Christoffels1.
Abstract
To elucidate cancer pathogenesis and its mechanisms at the molecular level, the collecting and characterization of large individual patient tissue cohorts are required. Since most pathology institutes routinely preserve biopsy tissues by standardized methods of formalin fixation and paraffin embedment, these archived FFPE tissues are important collections of pathology material that include patient metadata, such as medical history and treatments. FFPE blocks can be stored under ambient conditions for decades, while retaining cellular morphology, due to modifications induced by formalin. However, the effect of long-term storage, at resource-limited institutions in developing countries, on extractable protein quantity/quality has not yet been investigated. In addition, the optimal sample preparation techniques required for accurate and reproducible results from label-free LC-MS/MS analysis across block ages remains unclear. This study investigated protein extraction efficiency of 1, 5, and 10-year old human colorectal carcinoma resection tissue and assessed three different gel-free protein purification methods for label-free LC-MS/MS analysis. A sample size of n = 17 patients per experimental group (with experiment power = 0.7 and α = 0.05, resulting in 70% confidence level) was selected. Data were evaluated in terms of protein concentration extracted, peptide/protein identifications, method reproducibility and efficiency, sample proteome integrity (due to storage time), as well as protein/peptide distribution according to biological processes, cellular components, and physicochemical properties. Data are available via ProteomeXchange with identifier PXD017198. The results indicate that the amount of protein extracted is significantly dependent on block age (p < 0.0001), with older blocks yielding less protein than newer blocks. Detergent removal plates were the most efficient and overall reproducible protein purification method with regard to number of peptide and protein identifications, followed by the MagReSyn® SP3/HILIC method (with on-bead enzymatic digestion), and lastly the acetone precipitation and formic acid resolubilization method. Overall, the results indicate that long-term storage of FFPE tissues (as measured by methionine oxidation) does not considerably interfere with retrospective proteomic analysis (p > 0.1). Block age mainly affects initial protein extraction yields and does not extensively impact on subsequent label-free LC-MS/MS analysis results.Entities:
Keywords: LC-MS/MS; SP3/HILIC-on-bead-digestion; acetone precipitation and formic acid resolubilization; detergent removal plates; formalin-fixed paraffin-embedded proteomics; mass spectrometry
Mesh:
Substances:
Year: 2021 PMID: 34257588 PMCID: PMC8262168 DOI: 10.3389/pore.2021.622855
Source DB: PubMed Journal: Pathol Oncol Res ISSN: 1219-4956 Impact factor: 3.201
Information of the FFPE specimens selected for analysis.
| Patient number | Block age (years) | Patient age (years) | Gender | Diagnosis | Grade | Stage | Location |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 75 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 2 | 1 | 81 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 3 | 1 | 68 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 4 | 1 | 42 | M | Adenocarcinoma | Low-grade | IVA | Left colon |
| 5 | 1 | 80 | F | Adenocarcinoma | Low-grade | I | Left colon |
| 6 | 1 | 79 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 7 | 1 | 49 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 8 | 1 | 40 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 9 | 1 | 56 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 10 | 1 | 79 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 11 | 1 | 64 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 12 | 1 | 53 | M | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 13 | 1 | 78 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 14 | 1 | 51 | F | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 15 | 1 | 31 | M | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 16 | 1 | 73 | F | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 17 | 1 | 54 | F | Adenocarcinoma | Low-grade | IIIC | Left colon |
| 18 | 5 | 51 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 19 | 5 | 56 | F | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 20 | 5 | 86 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 21 | 5 | 59 | M | Adenocarcinoma | Low-grade | IIC | Left colon |
| 22 | 5 | 67 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 23 | 5 | 82 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 24 | 5 | 49 | F | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 25 | 5 | 54 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 26 | 5 | 58 | M | Adenocarcinoma | Low-grade | IIC | Left colon |
| 27 | 5 | 44 | F | Adenocarcinoma | Low-grade | I | Left colon |
| 28 | 5 | 50 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 29 | 5 | 74 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 30 | 5 | 54 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 31 | 5 | 47 | F | Adenocarcinoma | Low-grade | IIIA | Left colon |
| 32 | 5 | 55 | M | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 33 | 5 | 83 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 34 | 5 | 60 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 35 | 10 | 69 | M | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 36 | 10 | 47 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 37 | 10 | 58 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 38 | 10 | 83 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 39 | 10 | 57 | F | Adenocarcinoma | High-grade | IIA | Right colon |
| 40 | 10 | 46 | F | Adenocarcinoma | High-grade | IIA | Right colon |
| 41 | 10 | 77 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 42 | 10 | 63 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 43 | 10 | 67 | M | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 44 | 10 | 50 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 45 | 10 | 42 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 46 | 10 | 71 | F | Adenocarcinoma | Low-grade | IIA | Left colon |
| 47 | 10 | 70 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 48 | 10 | 69 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
| 49 | 10 | 62 | F | Adenocarcinoma | Low-grade | IIA | Right colon |
| 50 | 10 | 78 | M | Adenocarcinoma | Low-grade | IIIB | Left colon |
| 51 | 10 | 33 | M | Adenocarcinoma | Low-grade | IIA | Left colon |
FIGURE 1Colonic adenocarcinoma resection tissue samples. Representative H&E stained sections of patient cases/block ages analyzed in this study. (A) 1-year-old block. (B) 5-year-old block, and (C) 10-year-old block at ×100 magnification.
FIGURE 2Experimental design and workflow used to evaluate the effects of block age and different sample processing methods. FFPE human colorectal carcinoma resection tissues from 17 patients per block age (1, 5, and 10-year old blocks) were cut and tumor areas were manually micro-dissected for analysis. From each patient, tissue sections, which corresponded to approximately 25 mm3 tissue per patient/sample, were cut per sample. Protein was extracted and quantified, after which each patient sample was split in three, for subsequent sample processing by either the APFAR, DRP, or SP3/HILIC methods. Resultant peptides were analyzed via LC-MS/MS and data analysis was performed on all sample MS/MS spectra.
FIGURE 3BCA total protein quantitation assay results for the different block ages. Protein was extracted from approximately 25 mm3 patient tumor tissue using 500 µl protein extraction buffer per sample (n = 17 patients per group, p < 0.0001). The blue bars indicate protein yield from 1-year-old FFPE blocks, the red bars indicate protein yield from 5-year-old FFPE blocks, and the green bars indicate protein yield from 10-year-old FFPE blocks. The red dotted line indicates the average protein yield obtained from the 10-year-old FFPE blocks, which is 1.65 mg/ml protein.
FIGURE 4Comparison of the number of peptides and proteins identified for the different protein purification methods for each block age. (A) Box and whiskers plots of the number of peptides identified (for all 17 patient cases) per block age (p < 0.03 for 1 and 10-year-old blocks), and protein purification method (p = 0.0125 for DRP). (B) Box and whiskers plots of the number of proteins identified (for all 17 patient cases) per block age (p = 0.0002 for 1-year-old blocks) and protein purification method (p > 0.05 for all methods). Blue boxplots refer to APFAR samples; Red boxplots refer to DRP samples; Green boxplots refer to SP3/HILIC samples. For all boxplots, 5-year-old samples are represented by dots; 10-year-old samples are represented by diagonal lines.
Known proteins deregulated in colon cancer.
| % Occurrence within 17 patient samples | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APFAR | DRP | HILIC | |||||||||||
| Main accession | Gene name | Protein name | MW (kDa) | Comments | 1 year old | 5 year old | 10 year old | 1 year old | 5 year old | 10 year old | 1 year old | 5 year old | 10 year old |
| O95994 | AGR2 | Anterior gradient protein 2 homologue | 19.97 | Downregulated in CRC [ | 88 | 100 | 94 | 94 | 100 | 94 | 100 | 94 | 100 |
| Q13951 | CBFB | Core-binding factor subunit beta | 21.49 | Frequently overexpressed in CRC [ | 12 | 41 | 24 | 35 | 35 | 47 | 0 | 12 | 6 |
| P08174 | CD55; DAF | Complement decay-accelerating factor | 41.37 | Upregulated in CRC [ | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| P10645 | CHGA | Chromogranin-A | 50.66 | Downregulated in CRC [ | 29 | 29 | 18 | 18 | 18 | 18 | 24 | 18 | 18 |
| A8K7I4 | CLCA1 | Calcium-activated chloride channel regulator 1 | 100.16 | Regulator of calcium channels, frequently downregulated in CRC [ | 59 | 53 | 41 | 59 | 59 | 47 | 53 | 53 | 47 |
| Q96KP4 | CNDP2 | Cytosolic non-specific dipeptidase | 52.84 | Overexpressed in CRC [ | 82 | 88 | 94 | 100 | 88 | 100 | 94 | 94 | 100 |
| P07148 | FABP1 | FABP1 protein | 14.20 | Downregulated in CRC [ | 100 | 100 | 71 | 94 | 100 | 88 | 94 | 100 | 88 |
| Q9Y6R7 | FCGBP | IgGFc-binding protein | 571.64 | Downregulated in CRC [ | 76 | 94 | 82 | 76 | 94 | 76 | 82 | 88 | 82 |
| P56470 | LGALS4 | Galectin-4 | 35.92 | Downregulated in CRC [ | 100 | 100 | 100 | 100 | 100 | 100 | 94 | 100 | 100 |
| P09429 | HMGB1 | High mobility group protein B1 | 24.88 | Overexpression in CRC correlates with poor prognosis [ | 76 | 88 | 76 | 100 | 100 | 94 | 94 | 82 | 94 |
| P01042 | KNG1 | Kininogen-1 | 71.91 | Frequently overexpressed in CRC [ | 29 | 41 | 53 | 53 | 59 | 82 | 29 | 47 | 65 |
| Q9UHB6 | LIMA1 | LIM domain and actin-binding protein 1 | 85.17 | Downregulated in CRC [ | 0 | 0 | 6 | 0 | 0 | 24 | 6 | 6 | 0 |
| P15941 | MUC-1 | Mucin-1 | 122.03 | Frequently overexpressed in CRC, marker of poor prognosis [ | 0 | 6 | 12 | 6 | 6 | 12 | 0 | 6 | 6 |
| Q02817 | MUC-2 | Mucin-2 | 539.96 | Downregulation correlates with proliferation markers and with poor prognosis [ | 59 | 59 | 76 | 71 | 65 | 71 | 65 | 71 | 76 |
| P06748 | NPM1 | Nucleophosmin | 32.55 | Protein involved in carcinogenesis, overexpressed in CRC [ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Q6UX06 | OLFM4 | Olfactomedin-4 | 57.24 | Protein overexpressed in CRC [ | 29 | 18 | 29 | 35 | 24 | 29 | 29 | 24 | 29 |
| Q9Y617 | PSAT1 | Phosphoserine aminotransferase | 40.40 | Upregulated in CRC [ | 0 | 0 | 6 | 18 | 12 | 12 | 18 | 12 | 18 |
| P53992 | Sec24C | Protein transport protein Sec24C | 118.25 | Overexpressed in early CRC stages, while downregulated in advanced CRC stages [ | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 0 | 0 |
| P36952 | SERPIN B5 | Serpin B5 | 42.07 | Upregulated in CRC [ | 29 | 6 | 29 | 35 | 6 | 29 | 29 | 6 | 29 |
| P10599 | TXN | Thioredoxin | 11.73 | Frequently overexpressed in CRC [ | 94 | 100 | 100 | 94 | 100 | 100 | 94 | 94 | 94 |
FIGURE 5Physicochemical properties of identified peptides for all experimental conditions (n = 17 patients per group). (A) Hydropathicity based on GRAVY scoring matrix. (B) Molecular weight (MW). (C) Isoelectric point (pI). Blue boxplots refer to APFAR samples; Red boxplots refer to DRP samples; Green boxplots refer to HILIC samples. For all boxplots, 5-year-old samples are represented by dots; 10-year-old samples are represented by diagonal lines.
FIGURE 6Correlation of protein abundance between all protein purification methods for each patient sample. (A) Correlation of protein abundance for all protein purification methods for 1-year-old blocks/samples (n = 17 patients per group). (B) Correlation of protein abundance for all protein purification methods for 5-year-old blocks/samples (n = 17 patients per group). (C) Correlation of protein abundance for all protein purification methods for 10-year-old blocks/samples (n = 17 patients per group). The Pearson correlation coefficients (r 2) are indicated on each plot and plot axes values are the normalized NSAF values for proteins present in both condition compared per plot.
FIGURE 7PCA plots for all block ages and protein purification methods. The NSAF values for proteins identified from each patient case were normalized and dimensionality reduced by principal component analysis of the datasets. (A) PCA plot of all block age (1-year-old = red; 5-year-old = green; 10-year-old = blue) samples processed via the APFAR method. (B) PCA plot of all block age (1-year-old = red; 5-year-old = green; 10-year-old = blue) samples processed via the DRP method. (C) PCA plot of all block age (1-year-old = red; 5-year-old = green; 10-year-old = blue) samples processed via the HILIC method. (D) PCA plot of 1-year-old samples for all protein purification methods (APFAR = red; DRP = green; HILIC = blue). (E) PCA plot of 5-year-old samples for all protein purification methods (APFAR = red; DRP = green; HILIC = blue). (F) PCA plot of 10-year-old samples for all protein purification methods (APFAR = red; DRP = green; HILIC = blue).
FIGURE 8Gene Ontology annotation profiles for proteins identified from all block ages and protein purification methods. (A) GO profiles according to biological processes. (B) GO profiles according to cellular components. The average proportions for all 17 patients per condition are shown with error bars indicating the standard deviation. Blue bars refer to APFAR samples; Red bars refer to DRP samples; Green bars refer to HILIC samples. For all samples, 5-year-old samples are represented by dots; 10-year-old samples are represented by diagonal lines.